Despite decades of progress in decreasing rates of HIV vertical transmission globally, new paediatric infections continue to occur. Postnatal antiretroviral prophylaxis (PNP) remains a critical component of the toolbox available to prevent vertical transmission of HIV. Global guidelines have evolved over the years to better tailor PNP to the changing transmission dynamics influenced by greater coverage for maternal ART, longer duration of breastfeeding as well as persisting delayed ART initiation or suboptimal adherence during pregnancy or breastfeeding. Since 2016 WHO Guidelines have included Enhanced postnatal prophylaxis (ePNP) for infants at increased risk of HIV transmission. While WHO recommendations have been widely adopted, challenges persist with identifying infants at ‘high risk’ and providing ePNP with existing formulations. As a result, countries have adopted a variety of different approaches which may include triple-regimens, longer duration of prophylaxis or simplified approaches without risk-stratification, all resulting in market fragmentation and unreliable supply of commodities. Recent strides made in using novel ARV for pre-exposure Prophylaxis (PreP), have inspired the paediatric HIV community and provided a new impetus to review PNP approaches and explore innovative strategies for the future. Efforts to further reduce the risk of sexually acquired HIV in adults have recently led to the regulatory approval of injectable Cabotegravir extended-release suspension, following the results of 2 randomized controlled trials which demonstrated high efficacy in reducing HIV acquisition risk. In addition, a robust and dynamic pipeline of new antiretrovirals and broadly neutralizing antibodies holds promise for the future of PrEP and provides a compelling rationale to consider some of these agents for postnatal prophylaxis. To date, the scientific community has not identified a validated surrogate for risk of vertical transmission, consequently, very large clinical trials are required to support use of new regimens for PNP. This has prevented the development and introduction of better paediatric prevention regimens since the early investigations of nevirapine in newborns and breastfeeding infants. Overcoming this impasse in PNP innovation will require adaptive study designs or mixed methodologies to study strategies that combine currently approved ARVs for paediatric HIV treatment or consider future agents with novel drug delivery technologies.